Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2049277 | 1.00 | CTSK (0.61) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL4042455 | 1.00 | CTSK (0.61) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL1467769 | 0.91 | CA1 (0.71) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL3487489 | 0.91 | CA1 (0.71) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL3487968 | 0.91 | CA1 (0.71) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL6187601 | 0.90 | CTSK (0.56) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL30175163 | 0.90 | CA1 (0.66) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL5556389 | 0.90 | CA1 (0.66) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL19024479 | 0.89 | HSD11B1 (0.54) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL1649898 | 0.88 | CTSK (0.61) | CTSKHSD11B1CYP2C9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133225-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-1689752-B1 | PYRAZOLOPYRIMIDINES | PFIZER LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| EP-0394685-A2 | (S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid | WARNER-LAMBERT COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4916141-A | ANTIBACTERIAL | WARNER-LAMBERT COMPANY (US) | 1990-04-10 | — | — | US | disclosed |
| US-4851418-A | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0304087-A2 | Quinolone and naphthyridine antibacterial agents containing an alpha-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | CTSK 146/4885HSD11B1 491/4885CYP2C9 76/4885 |
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | CTSK 3122/4885HSD11B1 3467/4885CYP2C9 229/4885 |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | ABCB11, PCSK9, SLC10A1 | CTSK 146/4885HSD11B1 491/4885CYP2C9 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.